Skip to main content

Clidinium Disease Interactions

There are 10 disease interactions with clidinium.

Major

Anticholinergics (applies to clidinium) arrhythmias

Major Potential Hazard, High plausibility.

Patients with tachycardia should be supervised closely during treatment with anticholinergic agents. Tachycardia is produced by blocking normal vagal inhibition of the SA node. Paradoxically, bradycardia may occur due to central vagal stimulation which may occur prior to peripheral cholinergic blockade.

References

  1. Blumensohn R, Razoni G, Shalev A, Munitz H (1986) "Bradycardia due to trihexyphenidyl hydrochloride." Drug Intell Clin Pharm, 20, p. 786-7
  2. Voinov H, Elefante V, Mujica R (1992) "Sinus bradycardia related to the use of benztropine mesylate." Am J Psychiatry, 149, p. 711
  3. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
Major

Anticholinergics (applies to clidinium) autonomic neuropathy

Major Potential Hazard, High plausibility.

Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males. Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.

References

  1. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
Major

Anticholinergics (applies to clidinium) GI obstruction

Major Potential Hazard, High plausibility. Applicable conditions: Esophageal Obstruction, Gastrointestinal Obstruction

Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus. Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.

References

  1. Bantz EW, Dolen WK, Chadwick EW, Nelson HS (1987) "Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance." Ann Allergy, 59, p. 341-6
  2. Simons FE, Frith EM, Simons KJ (1982) "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol, 70, p. 458-64
  3. Blamoutier J (1978) "Comparative trial of two antihistamines, mequitazine and brompheniramine." Curr Med Res Opin, 5, p. 366-70
  4. (1977) "Azatadine (optimine)--a new antihistamine." Med Lett Drugs Ther, 19, p. 77-9
  5. (2002) "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories
  6. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
  7. (2002) "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc
  8. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  9. (2001) "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories
  10. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  11. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  12. (2001) "Product Information. Optimine (azatadine)." Schering Corporation
  13. Mevorach D (1992) "Adverse effects of atropine sulfate autoinjection." Ann Pharmacother, 26, p. 564
  14. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
  15. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
  16. (2001) "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company
View all 16 references
Major

Anticholinergics (applies to clidinium) glaucoma

Major Potential Hazard, High plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present. Because anticholinergics cause mydriasis, they may exacerbate these conditions.

References

  1. Schuller DE, Turkewitz D (1986) "Adverse effects of antihistamines." Postgrad Med, 79, p. 75-86
  2. (2002) "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories
  3. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
  4. (2002) "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham
  5. (2002) "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc
  6. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  7. (2001) "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories
  8. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  9. (2001) "Product Information. Optimine (azatadine)." Schering Corporation
  10. O'Connor PS, Mumma JV (1985) "Atropine toxicity." Am J Ophthalmol, 99, p. 613-4
  11. Clearkin LG (1992) "Angle closure glaucoma precipitated by atropine." Arch Intern Med, 152, p. 880
  12. Berdy GJ, Berdy SS, Odin LS, Hirst LW (1991) "Angle closure glaucoma precipitated by aerosolized atropine." Arch Intern Med, 151, p. 1658-60
  13. Pecora JL (1979) "Malignant glaucoma worsened by miotics in a postoperative angle- closure glaucoma patient." Ann Ophthalmol, 11, p. 1412-4
  14. Holland MG (1974) "Autonomic drugs in ophthalmology: some problems and promises. Section II: Anticholinergic drugs." Ann Ophthalmol, 6, p. 661-4
  15. Kanto J (1983) "New aspects in the use of atropine." Int J Clin Pharmacol Ther Toxicol, 21, p. 92-4
  16. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
  17. (2001) "Product Information. Compazine (prochlorperazine)." SmithKline Beecham
  18. Goldstein JH (1971) "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin, 11, p. 13-34
  19. (2001) "Product Information. Cogentin (benztropine)." Merck & Co., Inc
  20. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
  21. (2001) "Product Information. Moban (molindone)." Gate Pharmaceuticals
  22. "Product Information. Orap (pimozide)." Gate Pharmaceuticals
  23. (2001) "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company
View all 23 references
Major

Anticholinergics (applies to clidinium) obstructive uropathy

Major Potential Hazard, High plausibility. Applicable conditions: Urinary Retention

In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy. Dysuria may occur and may require catheterization. Also, anticholinergic drugs may aggravate partial obstructive uropathy. Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.

References

  1. Bantz EW, Dolen WK, Chadwick EW, Nelson HS (1987) "Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance." Ann Allergy, 59, p. 341-6
  2. Schuller DE, Turkewitz D (1986) "Adverse effects of antihistamines." Postgrad Med, 79, p. 75-86
  3. (2002) "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories
  4. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
  5. (2002) "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham
  6. (2002) "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc
  7. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  8. (2001) "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories
  9. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  10. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  11. (2001) "Product Information. Optimine (azatadine)." Schering Corporation
  12. Shutt LE, Bowes JB (1979) "Atropine and hyoscine." Anaesthesia, 34, p. 476-90
  13. O'Kelly SW, Spargo PM (1991) "Postoperative urinary retention in men." BMJ, 302, p. 1403-4
  14. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
  15. (2001) "Product Information. Compazine (prochlorperazine)." SmithKline Beecham
  16. (2001) "Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals
  17. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
  18. (2001) "Product Information. Moban (molindone)." Gate Pharmaceuticals
  19. "Product Information. Orap (pimozide)." Gate Pharmaceuticals
  20. (2001) "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company
View all 20 references
Major

Anticholinergics (applies to clidinium) tardive dyskinesia

Major Potential Hazard, High plausibility.

Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms. Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly. If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.

References

  1. Brait KA, Zagerman AJ (1977) "Dyskinesias after antihistamine use ." N Engl J Med, 296, p. 111
  2. Jones B, Lal S (1985) "Tardive dyskinesia uncovered after ingestion of Sominex, an over-the- counter drug." Can J Psychiatry, 30, p. 370-1
  3. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  4. Yassa R (1985) "Antiparkinsonian medication withdrawal in the treatment of tardive dyskinesia: a report of three cases." Can J Psychiatry, 30, p. 440-2
  5. Burnett GB, Prange AJ Jr, Wilson IC, Jolliff LA, Creese IC, Synder SH (1980) "Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism." Neuropsychobiology, 6, p. 109-20
  6. Kiloh LG, Smith JS, Williams SE (1973) "Antiparkinson drugs as causal agents in tardive dykinesia." Med J Aust, 2, p. 591-3
  7. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
View all 7 references
Major

Antiperistaltic agents (applies to clidinium) infectious diarrhea

Major Potential Hazard, High plausibility. Applicable conditions: Infectious Diarrhea/Enterocolitis/Gastroenteritis

The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria. These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics. Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged. In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool. Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.

References

  1. Brown JW (1979) "Toxic megacolon associated with loperamide therapy." JAMA, 241, p. 501-2
  2. Walley T, Milson D (1990) "Loperamide related toxic megacolon in Clostridium difficile colitis." Postgrad Med J, 66, p. 582
  3. (2001) "Product Information. Imodium (loperamide)." Janssen Pharmaceuticals
  4. Marshall WF Jr, Rosenthal P, Merritt RJ (1989) "Atropine therapy and paralytic ileus in an infant." J Pediatr Gastroenterol Nutr, 9, p. 532-4
  5. (1975) "Lomotil for diarrhea in children." Med Lett Drugs Ther, 17, p. 104
  6. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
View all 6 references
Moderate

Antimuscarinics (applies to clidinium) psychoses

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis

Toxic psychosis manifested as confusion, disorientation, agitation, excitation, memory impairment, delusions and hallucinations may develop at toxic and therapeutic dosages of antimuscarinic agents. Therapy with these agents should be administered cautiously in patients with mental disorders receiving antimuscarinic agents for control of drug-induced extrapyramidal effects, especially at the beginning of therapy or during dosage adjustment. Psychiatric deterioration and psychotic flare-ups have also been reported following withdrawal of therapy. Symptoms include delusions, hallucinations, aggression or violent behavior, and suicidal tendencies. In high dosages, antimuscarinic agents may sometimes produce euphorigenic effects. For this reason, it can be a drug of abuse.

References

  1. Jellinek T, Gardos G, Cole JO (1981) "Adverse effects of antiparkinson drug withdrawal." Am J Psychiatry, 138, p. 1567-71
  2. Goggin DA, Solomon GF (1979) "Trihexyphenidyl abuse for euphorigenic effect." Am J Psychiatry, 136, p. 459-60
  3. Macvicar K (1977) "Abuse of antiparkinsonian drugs by psychiatric patients." Am J Psychiatry, 134, p. 809-11
  4. Craig DH, Rosen P (1981) "Abuse of antiparkinsonian drugs." Ann Emerg Med, 10, p. 98-100
  5. Pullen GP, Best NR, Maguire J (1984) "Anticholinergic drug abuse: a common problem?" Br Med J (Clin Res Ed), 289, p. 612-3
  6. Rubinstein JS (1978) "Abuse of antiparkinsonism drugs. Feigning of extrapyramidal symptoms to obtain trihexyphenidyl." JAMA, 239, p. 2365-6
  7. McInnis M, Petursson H (1984) "Trihexyphenidyl dependence." Acta Psychiatr Scand, 69, p. 538-42
  8. Mohan D, Mohandas E, Dube S (1981) "Trihexyphenidyl abuse." Br J Addict, 76, p. 195-7
  9. Kaminer Y, Munitz H, Wijsenbeek H (1982) "Trihexyphenidyl (Artane) abuse: euphoriant and anxiolytic." Br J Psychiatry, 140, p. 473-4
  10. Warnes H (1967) "Toxic psychosis due to antiparkinsonian drugs." Can Psychiatr Assoc J, 12, p. 323-6
  11. Hidalgo HA, Mowers RM (1990) "Anticholinergic drug abuse." DICP, 24, p. 40-1
  12. Wilcox JA (1983) "Psychoactive properties of benztropine and trihexyphenidyl." J Psychoactive Drugs, 15, p. 319-21
  13. Laski E, Taleporos E (1977) "Anticholinergic psychosis in a bilingual: a case study." Am J Psychiatry, 134, p. 1038-40
  14. Brower KJ (1987) "Smoking of prescription anticholinergic drugs." Am J Psychiatry, 144, p. 383
  15. Baker LA, Cheng LY, Amara IB (1983) "The withdrawal of benztropine mesylate in chronic schizophrenic patients." Br J Psychiatry, 143, p. 584-90
  16. Moreau A, Jones BD, Banno V (1986) "Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia." Can J Psychiatry, 31, p. 339-41
  17. Yassa R (1985) "Antiparkinsonian medication withdrawal in the treatment of tardive dyskinesia: a report of three cases." Can J Psychiatry, 30, p. 440-2
  18. Ananth JV, Jain RC (1973) "Benztropine psychosis." Can Psychiatr Assoc J, 18, p. 409-14
  19. Woody GE, O'Brien CP (1974) "Anticholinergic toxic psychosis in drug abusers treated with benztropine." Compr Psychiatry, 15, p. 439-42
  20. (2001) "Product Information. Cogentin (benztropine)." Merck & Co., Inc
  21. Kulik AV, Wilbur R (1982) "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry, 6, p. 75-82
  22. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
View all 22 references
Minor

Anticholinergics (applies to clidinium) hypertension

Minor Potential Hazard, Moderate plausibility.

Cardiovascular effects of anticholinergics may exacerbate hypertension. Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.

References

  1. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  2. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  3. (2001) "Product Information. Marezine (cyclizine)." Glaxo Wellcome
  4. Valentin N, Staffeldt H, Kyst A (1984) "Effect of i.v. atropine on cardiac rhythm, heart rate, blood pressure and airway secretion during isoflurane anaesthesia." Acta Anaesthesiol Scand, 28, p. 621-4
  5. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
  6. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
  7. (2002) "Product Information. Atropisol (atropine ophthalmic)." Ciba Vision Ophthalmics
View all 7 references
Minor

Atropine-like agents (applies to clidinium) fever

Minor Potential Hazard, Moderate plausibility.

Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis. Therapy with atropine-like agents should be administered cautiously in febrile patients.

References

  1. Stadnyk AN, Glezos JD (1983) "Drug-induced heat stroke." Can Med Assoc J, 128, p. 957-9
  2. Sarnquist F, Larson CP Jr (1973) "Drug-induced heat stroke." Anesthesiology, 39, p. 348-50
  3. Lee BS (1986) "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry, 47, p. 571
  4. Forester D (1978) "Fatal drug-induced heat stroke." JACEP, 7, p. 243-4
  5. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
  6. (2001) "Product Information. Cogentin (benztropine)." Merck & Co., Inc
View all 6 references

Clidinium drug interactions

There are 199 drug interactions with clidinium.

Clidinium alcohol/food interactions

There are 2 alcohol/food interactions with clidinium.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.